Approximately 10% of children with Escherichia coli 0157:H7 infection develop the hemolytic uremic syndrome (HUS). The pathophysiologic cascade leading from gastrointestinal infection with this Shiga-toxigenic organism to systemic vascular injury is incompletely understood. There are no suitable animal models in which glomerular thrombotic lesions result from enteral or parenteral challenge with Shiga-toxin, or enteral challenge with E. coli 0157:H7 or other Shiga-toxigenic E. Coli. Escherichia coli 0157:H7 infection remains frequently diagnosed in western Washington children before HUS ensues, thereby identifying a population of children at high risk of developing microangiopathic sequelae within a week. This study will examine such children, and assay a selected variety of circulating, urinary and fecal inflammatory, prothrombotic, vasoactive, genetic, and microbial factors which could plausibly play, initiate and/or perpetuate microangiopathic abnormalities leading to HUS. These include cytokines, thrombogenic factors, fibrinolytic factors, markers of endothelial cell injury/activation, arachidonic acid metabolites, circulating endotoxin levels, platelet activating factor concentrations, expression of host cell antigens, concentrations of E. coli 0157:H7 and of fecal free toxin, and toxin genotype. In addition to defining the elements of the cascade leading to kidney failure in children with E. coli 0157:H7 infection, this research could also identify the group at highest risk of developing HUS following enteric infection E. coli 0157:H7, thereby suggesting children most likely to benefit from novel therapeutic strategies.
Showing the most recent 10 out of 23 publications
